Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is one of half a dozen drugmakers that have been rolling out generics of Eli Lilly’s ($LLY) top-selling blockbuster Cymbalta. The others are going to roll past the Israeli drugmaker after it recalled more than 1 million bottles of the antidepressant. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.76% in last session and finished the day at $49.95. Traded volume was 6.81million shares in the last session and the average volume of the stock remained 7.34million shares. The beta of the stock remained 0.59.

European stocks look set for a flat start on Tuesday amid fresh concerns over Ukraine and disappointing sales figures from companies such as L’Oreal and Roche. Trading later in the day may be impacted by US reports on consumer prices, homebuilder confidence and New York manufacturing activity as well as earnings announcements from companies such as Coca-Cola and Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) rose 0.28 percent to $97.14 Monday on volume of 8.62million shares. The intra-day range of the stock was $96.25 to $97.36. Johnson & Johnson (NYSE:JNJ) has a market capitalization of $274.80billion.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. MNKD also gets F’s in Analyst Earnings Revisions and Cash Flow. MannKind Corporation (NASDAQ:MNKD)’s stock on Apr 14, 2014 reported a decrease of -1.87% to the closing price of $6.29. Its fifty two weeks range is $3.72 -$8.70. The total market capitalization recorded $2.37billion. The overall volume in the last trading session was 9.12million shares. In its share capital, MNKD has 377.21million outstanding shares.

Abbott Laboratories (NYSE:ABT) is scheduled to be releasing its Q114 earnings data on Wednesday, April 16th. Analysts expect Abbott Laboratories (NYSE:ABT) to post earnings of $0.36 per share and revenue of $5.29 billion for the quarter. Analysts at Jefferies Group reiterated a “buy” rating on shares of Abbott Laboratories (NYSE:ABT) in a research note on Monday. On Monday, shares of Abbott Laboratories (NYSE:ABT) advanced 1.94% to close the day at $37.74. Company return on investment (ROI) is 8.00% and its monthly performance is recorded as -2.58%. Abbott Laboratories (NYSE:ABT) quarterly revenue growth is -2.93%.